149 results on '"Hudis, Clifford"'
Search Results
2. Data from Obesity-associated Breast Inflammation among Hispanic/Latina Breast Cancer Patients
3. Data from Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women
4. Data from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer
5. Data from Dietary Polyphenols Suppress Elevated Levels of Proinflammatory Mediators and Aromatase in the Mammary Gland of Obese Mice
6. Supplementary Data from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer
7. Data from Obesity Is Associated with Inflammation and Elevated Aromatase Expression in the Mouse Mammary Gland
8. Supplementary Figure 2 from Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women
9. Data from Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer
10. Data from A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
11. Supplementary Table 1 from Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy
12. Supplementary Figure Legends 1-2 from Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women
13. Supplementary Appendix 1 from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer
14. Supplementary Tables 1 - 3 from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer
15. Supplementary Figure 1 from Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer
16. Supplementary Data from Obesity-associated Breast Inflammation among Hispanic/Latina Breast Cancer Patients
17. Data from Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy
18. Supplementary Data from Obesity Is Associated with Inflammation and Elevated Aromatase Expression in the Mouse Mammary Gland
19. Supplementary Table 1 from A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
20. Supplementary Figure 1 from Increased Levels of COX-2 and Prostaglandin E2 Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women
21. Supplemental Table from MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
22. Supplemental Figures from MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
23. Data from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
24. Supplemental Figure 5 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
25. Supplementary Tables 1 - 5 from Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
26. Supplementary Tables S1-S3 from The Genomic Landscape of Male Breast Cancers
27. Supplemental Methods from MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
28. Supplementary Data from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
29. Supplementary Table 3 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
30. Supplementary Table 1 from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
31. Supplementary Tables S11 and S12 from The Genomic Landscape of Male Breast Cancers
32. Supplementary Legend from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
33. Supplementary Data Files from Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
34. Supplementary Figure 1 from Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
35. Supplemental Figure 2 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
36. Supplementary Figure 1 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
37. Supplementary Figure 2 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
38. Supplementary Methods from A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors
39. Supplementary Table 1 from The 6q22.33 Locus and Breast Cancer Susceptibility
40. Supplementary Figures S6-S10 from The Genomic Landscape of Male Breast Cancers
41. Supplementary Table 2 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
42. Supplementary eTables from Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
43. Supplementary Figure 1 from Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
44. Supplemental Figure 4 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
45. Supplementary Table 1 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
46. Data from The 6q22.33 Locus and Breast Cancer Susceptibility
47. Supplementary Methods from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
48. Supplementary Methods from The Genomic Landscape of Male Breast Cancers
49. Supplementary Table 1 from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
50. Supplementary Figure Legend from Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.